ERBB2 and neoplasm: T-DM1 has diverse mechanisms: selective delivery to HER2+ tumor cells by DM1 for trastuzumab-mediated inhibition of HER2 signaling, inhibition of HER2 extracellular domain shedding, and induction of ADCC (Hunter et al., 2020) (Table 1).